Aufklappen
Schliessen
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
| Leser | Medien | |
|---|---|---|---|---|
| Di | Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-246 | 2 | GlobeNewswire (Europe) | |
| STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic... ► Artikel lesen | ||||
| 03.04. | Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents | 1 | GlobeNewswire (Europe) | |
| STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that... ► Artikel lesen | ||||
| KAROLINSKA DEVELOPMENT Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten! | LYNX | |||
► Artikel lesen | ||||
| 25.03. | Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer | 4 | GlobeNewswire (Europe) | |
| STOCKHOLM, March 25, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief... ► Artikel lesen | ||||
| 15.03. | Karolinska Development AB (publ): Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical | 7 | GlobeNewswire (Europe) | |
| STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical to commercialize Promimic's proprietary Hydroxyapatite... ► Artikel lesen | ||||
| 07.03. | Karolinska Development AB (publ): Karolinska Development's portfolio company Forendo Pharma announces positive results from a Phase Ia study of FOR 6219 | 4 | GlobeNewswire (Europe) | |
| STOCKHOLM, March 7, 2019. Karolinska Development's portfolio company Forendo Pharma today announces positive results from a Phase Ia study with the drug candidate FOR 6219 for the treatment of... ► Artikel lesen | ||||
| 27.02. | Karolinska Development AB (publ): New US investor joins Series C financing of Karolinska Development's portfolio company Aprea Therapeutics | 3 | GlobeNewswire (Europe) | |
| STOCKHOLM, February 27, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that funds managed by Janus Henderson Investors has joined its Series C financing as... ► Artikel lesen | ||||
| 22.02. | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin | 3 | GlobeNewswire (Europe) | |
| STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics... ► Artikel lesen | ||||
| 12.02. | Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North | 3 | GlobeNewswire (Europe) | |
| STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French... ► Artikel lesen | ||||
| 07.01. | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin | 3 | GlobeNewswire (Europe) | |
| STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients... ► Artikel lesen | ||||
| 02.12.18 | Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 246 | 7 | GlobeNewswire (Europe) | |
| STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society... ► Artikel lesen | ||||
| 07.11.18 | Karolinska Development AB (publ): Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease | 3 | GlobeNewswire (Europe) | |
| STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational... ► Artikel lesen | ||||
| 01.11.18 | BRIEF-Karolinska Development: Study With Tafoxiparin Did Not Achieve Primary Endpoint | - | Reuters.com | |
► Artikel lesen | ||||
| 22.10.18 | Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug | 10 | GlobeNewswire (Europe) | |
| STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing... ► Artikel lesen | ||||
| 15.10.18 | Karolinska Development AB (publ): Karolinska Development's portfolio company Pharmanest changes name and signs licensing agreement | 5 | GlobeNewswire (Europe) | |
| STOCKHOLM, October 15, 2018. Karolinska Development's portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé... ► Artikel lesen | ||||
| 24.09.18 | Karolinska Development AB (publ): Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North | 3 | GlobeNewswire (Europe) | |
| STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is... ► Artikel lesen | ||||
| 05.09.18 | Karolinska Development AB (publ): Vesalius Biocapital III Partners invests in Karolinska Development's portfolio company Forendo Pharma | 5 | GlobeNewswire (Europe) | |
| STOCKHOLM, September 5, 2018. Karolinska Development's portfolio company Forendo Pharma announces today that Vesalius Biocapital III Partners (Vesalius) joins Forendo Pharma's existing international... ► Artikel lesen | ||||
| 13.07.18 | XFRA FRA:New Instruments available on XETRA - 13.07.2018-002 | 26 | Xetra Newsboard | |
| The following instruments on XETRA do have their first trading day 13.07.2018 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am 13.07.2018 TrdMod InstCode Exch ISIN Name InstGrp InstType... ► Artikel lesen | ||||
| 04.07.18 | Karolinska Development AB (publ): Karolinska Development's portfolio company Forendo Pharma initiates clinical phase I study for endometriosis treatment | 23 | GlobeNewswire (Europe) | |
| STOCKHOLM, July 4, 2018. Karolinska Development's portfolio company Forendo Pharma today announces that it has received clinical trial authorization (CTA) from the Medicines and Healthcare products... ► Artikel lesen | ||||
| 17.06.18 | Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II combination study with APR-246 at hematology congress | 11 | GlobeNewswire (Europe) | |
| STOCKHOLM, June 17, 2018. Karolinska Development's portfolio company Aprea Therapeutics presents continued positive development for the candidate drug APR-246 in patients with TP53 Mutant Myelodysplastic... ► Artikel lesen | ||||
| 31.05.18 | Karolinska Development AB (publ): Karolinska Development's portfolio company Pharmanest out-licenses Canadian rights for SHACT to Acerus | 3 | GlobeNewswire (Europe) | |
| STOCKHOLM, May 31, 2018. Karolinska Development's portfolio company Pharmanest AB has announced that it has entered into an exclusive agreement with Acerus Pharmaceuticals Corporation pertaining... ► Artikel lesen | ||||
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von
Nachrichten • Aktienkurse • DAX • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer | Datenschutz • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage